Both companies have forward P/Es well below the average of the S&P 500, which is now a sky-high level of 18. They also are in favor with analysts, as 2015 and 2016 earnings estimates have been moving higher.
They both have been returning value to shareholders. Pfizer is expected to continue to pay its juicy dividend, even after its merger with Allergan. Mylan recently announced a $1 billion share buyback program.
But what else should investors take away from these two companies? Watch our short video below to learn more about these value stocks!
Follow us on StockTwits: http://stocktwits.com/ZacksResearch
Follow us on Twitter: https://twitter.com/ZacksResearch
Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch